Identification

Name
Temsirolimus
Accession Number
DB06287
Type
Small Molecule
Groups
Approved
Description

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.

Structure
Thumb
Synonyms
  • 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
External IDs
CCI-779
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-temsirolimusSolution25 mgIntravenousGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
ToriselLiquid25 mgIntravenousPfizer2008-01-11Not applicableCanada
ToriselKitWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2007-07-01Not applicableUs
ToriselInjection, solution, concentrate30 mgIntravenousPfizer2007-11-19Not applicableEu
International/Other Brands
Torisel
Categories
UNII
624KN6GM2T
CAS number
162635-04-3
Weight
Average: 1030.2871
Monoisotopic: 1029.602485741
Chemical Formula
C56H87NO16
InChI Key
CBPNZQVSJQDFBE-FUXHJELOSA-N
InChI
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
IUPAC Name
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
SMILES

Pharmacology

Indication

For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.

TargetActionsOrganism
ASerine/threonine-protein kinase mTOR
inhibitor
Human
Absorption

Infused intravenous over 30 - 60 minutes. Cmax is typically observed at the end of infusion

Volume of distribution

172 L in whole blood of cancer patients; both temsirolimus and sirolimus are extensive distributed partitioned into formed blood elements

Protein binding

87% bound to plasma proteins in vitro at a concentration of 100 ng/ml

Metabolism

Primarily metabolized by cytochrome P450 3A4 in the human liver. Sirolimus, an equally potent metabolite, is the primary metabolite in humans following IV infusion. Other metabolic pathways observed in in vitro temsirolimus metabolism studies include hydroxylation, reduction and demethylation.

Route of elimination

Excreted predominantly in feces (76%), 4.6% of drug and metabolites recovered in urine. 17% of drug was not recovered by either route following a 14-day sample collection.

Half life

Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.

Clearance

16.2 L/h (22%)

Toxicity

Temsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of temsirolimus greater than 25 mg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Temsirolimus.Investigational
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Temsirolimus.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe risk or severity of adverse effects can be increased when 4-(2-Aminoethyl)Benzenesulfonyl Fluoride is combined with Temsirolimus.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Temsirolimus.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Temsirolimus.Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Temsirolimus.Experimental
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Temsirolimus.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Temsirolimus.Experimental, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Temsirolimus.Investigational
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temsirolimus.Approved
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Temsirolimus.Approved
AmiodaroneThe metabolism of Temsirolimus can be decreased when combined with Amiodarone.Approved, Investigational
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Temsirolimus.Approved
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Temsirolimus.Approved
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.Approved
AprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Temsirolimus.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Temsirolimus.Approved, Investigational
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Temsirolimus.Approved, Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Temsirolimus.Approved, Investigational
AtomoxetineThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Atorvastatin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Temsirolimus.Investigational
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Temsirolimus.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Temsirolimus.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Temsirolimus.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Temsirolimus.Approved, Investigational
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Temsirolimus.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Temsirolimus.Approved, Withdrawn
BortezomibThe metabolism of Temsirolimus can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Temsirolimus can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Temsirolimus.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Temsirolimus.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Temsirolimus.Investigational, Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temsirolimus.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Temsirolimus.Approved
CamostatThe risk or severity of adverse effects can be increased when Camostat is combined with Temsirolimus.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Temsirolimus.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Temsirolimus.Experimental
CandoxatrilatThe risk or severity of adverse effects can be increased when Candoxatrilat is combined with Temsirolimus.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Temsirolimus.Approved
CarbamazepineThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Temsirolimus.Vet Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Temsirolimus.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Temsirolimus.Experimental
CeritinibThe serum concentration of Temsirolimus can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Temsirolimus.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Temsirolimus.Approved
CholesterolThe risk or severity of adverse effects can be increased when Cholesterol is combined with Temsirolimus.Experimental, Investigational
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Temsirolimus.Experimental
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Temsirolimus.Experimental
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Temsirolimus.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Temsirolimus.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Temsirolimus.Approved
ClemastineThe metabolism of Temsirolimus can be decreased when combined with Clemastine.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Temsirolimus.Approved
ClotrimazoleThe metabolism of Temsirolimus can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clozapine.Approved
CobicistatThe metabolism of Temsirolimus can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Temsirolimus.Approved
ConivaptanThe serum concentration of Temsirolimus can be increased when it is combined with Conivaptan.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Temsirolimus.Approved
CrizotinibThe metabolism of Temsirolimus can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Temsirolimus.Experimental
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.Approved
DabrafenibThe serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.Approved
DarexabanThe risk or severity of adverse effects can be increased when Darexaban is combined with Temsirolimus.Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Temsirolimus.Approved
DasatinibThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe risk or severity of adverse effects can be increased when Delanzomib is combined with Temsirolimus.Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Temsirolimus.Experimental
DelavirdineThe metabolism of Temsirolimus can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Temsirolimus.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temsirolimus.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temsirolimus.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Temsirolimus.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Temsirolimus.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Temsirolimus.Experimental
DihydroergotamineThe metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Temsirolimus can be decreased when combined with Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.Approved, Investigational
DoxycyclineThe metabolism of Temsirolimus can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Temsirolimus can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Temsirolimus.Approved
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Temsirolimus.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Temsirolimus.Approved
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Temsirolimus.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Temsirolimus.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus.Approved
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Temsirolimus.Experimental
EnzalutamideThe serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe risk or severity of adverse effects can be increased when Epigallocatechin Gallate is combined with Temsirolimus.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Temsirolimus.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Temsirolimus.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Temsirolimus.Approved, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Temsirolimus.Approved, Investigational
FaldaprevirThe risk or severity of adverse effects can be increased when Faldaprevir is combined with Temsirolimus.Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.Approved
FingolimodTemsirolimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Fluconazole.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Temsirolimus.Approved
FluvoxamineThe metabolism of Temsirolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Temsirolimus.Approved
FosaprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Temsirolimus.Approved
FosphenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Temsirolimus.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Temsirolimus.Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Temsirolimus.Experimental, Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Temsirolimus.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Temsirolimus.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Temsirolimus.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Temsirolimus.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Temsirolimus.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Temsirolimus.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Temsirolimus.Approved
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Temsirolimus.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Temsirolimus.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Temsirolimus.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Temsirolimus.Approved, Withdrawn
IdelalisibThe serum concentration of Temsirolimus can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe risk or severity of adverse effects can be increased when Idraparinux is combined with Temsirolimus.Investigational
ImatinibThe metabolism of Temsirolimus can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Temsirolimus.Investigational
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Temsirolimus.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Temsirolimus.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Temsirolimus.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Temsirolimus.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Temsirolimus.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Temsirolimus.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Temsirolimus.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Temsirolimus.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus.Approved
IsavuconazoniumThe metabolism of Temsirolimus can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Temsirolimus.Approved, Investigational, Withdrawn
IsradipineThe metabolism of Temsirolimus can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Temsirolimus can be increased when it is combined with Ivacaftor.Approved
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Temsirolimus.Approved
JosamycinThe risk or severity of adverse effects can be increased when Josamycin is combined with Temsirolimus.Approved, Investigational
KetoconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Temsirolimus.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Temsirolimus.Experimental
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Temsirolimus.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Leflunomide.Approved, Investigational
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.Approved
LetaxabanThe risk or severity of adverse effects can be increased when Letaxaban is combined with Temsirolimus.Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temsirolimus.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Temsirolimus.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Temsirolimus.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Temsirolimus.Approved
LovastatinThe metabolism of Temsirolimus can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Temsirolimus can be decreased when it is combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Temsirolimus.Illicit, Investigational, Withdrawn
MelagatranThe risk or severity of adverse effects can be increased when Melagatran is combined with Temsirolimus.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temsirolimus.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Temsirolimus.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Temsirolimus.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Temsirolimus.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Temsirolimus.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Temsirolimus.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Temsirolimus.Experimental
MifepristoneThe serum concentration of Temsirolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Temsirolimus.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Temsirolimus.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
MitotaneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Temsirolimus.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Temsirolimus.Experimental
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temsirolimus.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Temsirolimus.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
NefazodoneThe metabolism of Temsirolimus can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus.Approved
NetupitantThe serum concentration of Temsirolimus can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Temsirolimus can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Temsirolimus.Approved, Investigational
NilotinibThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Temsirolimus.Investigational
OlaparibThe metabolism of Temsirolimus can be decreased when combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Temsirolimus.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Temsirolimus.Experimental, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Temsirolimus.Investigational
OsimertinibThe serum concentration of Temsirolimus can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Temsirolimus.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Temsirolimus.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temsirolimus.Approved, Vet Approved
PalbociclibThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.Approved
PentobarbitalThe metabolism of Temsirolimus can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Temsirolimus.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Temsirolimus.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Temsirolimus.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Temsirolimus.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Temsirolimus can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Temsirolimus.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Temsirolimus.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Temsirolimus.Approved
PosaconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Temsirolimus.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Temsirolimus.Approved
PrimidoneThe metabolism of Temsirolimus can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Temsirolimus.Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Temsirolimus.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Temsirolimus.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Temsirolimus.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Temsirolimus.Approved
RacecadotrilThe risk or severity of adverse effects can be increased when Racecadotril is combined with Temsirolimus.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Temsirolimus.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Temsirolimus.Approved, Investigational
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Temsirolimus.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.Approved
RifabutinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Temsirolimus can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifaximin.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Temsirolimus.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Temsirolimus.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Temsirolimus.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Temsirolimus.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Temsirolimus.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Temsirolimus.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Temsirolimus.Approved
S-3304The risk or severity of adverse effects can be increased when S-3304 is combined with Temsirolimus.Investigational
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Temsirolimus.Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Temsirolimus.Approved, Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temsirolimus.Approved
SildenafilThe metabolism of Temsirolimus can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.Approved
SiltuximabThe serum concentration of Temsirolimus can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Temsirolimus.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Temsirolimus.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temsirolimus.Approved
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temsirolimus.Approved, Investigational
SivelestatThe risk or severity of adverse effects can be increased when Sivelestat is combined with Temsirolimus.Investigational
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Temsirolimus.Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Temsirolimus.Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Temsirolimus.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Temsirolimus.Investigational
St. John's WortThe serum concentration of Temsirolimus can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Temsirolimus can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Temsirolimus can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Temsirolimus.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Sunitinib.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Temsirolimus.Investigational
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Temsirolimus.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Temsirolimus.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Temsirolimus.Experimental, Investigational
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Temsirolimus.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Temsirolimus.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Temsirolimus.Approved, Withdrawn
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Temsirolimus.Experimental
TiclopidineThe metabolism of Temsirolimus can be decreased when combined with Ticlopidine.Approved
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.Approved, Investigational
TocilizumabThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTemsirolimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Temsirolimus.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Temsirolimus.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Temsirolimus.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Temsirolimus.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Temsirolimus.Investigational, Withdrawn
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Temsirolimus.Vet Approved
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Temsirolimus.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Temsirolimus.Approved, Experimental
UlinastatinThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Temsirolimus.Investigational
VenlafaxineThe metabolism of Temsirolimus can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Temsirolimus can be decreased when combined with Verapamil.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temsirolimus.Approved, Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Temsirolimus.Approved, Investigational
VoriconazoleThe metabolism of Temsirolimus can be decreased when combined with Voriconazole.Approved, Investigational
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Temsirolimus.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Temsirolimus.Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe risk or severity of adverse effects can be increased when Z-Val-Ala-Asp fluoromethyl ketone is combined with Temsirolimus.Experimental
ZiprasidoneThe metabolism of Temsirolimus can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Temsirolimus.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Temsirolimus.Approved
Food Interactions
Not Available

References

Synthesis Reference

Kwang-Chung Lee, Ting-Huei Lee, Yen-Shih Tung, Chia-Chen Kao, Tzu-Ai Lee, "Process for preparation of temsirolimus." U.S. Patent US20100249415, issued September 30, 2010.

US20100249415
General References
  1. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L: Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007 Nov;47(11):1430-9. Epub 2007 Oct 3. [PubMed:17913896]
External Links
Human Metabolome Database
HMDB15632
KEGG Drug
D06068
KEGG Compound
C15182
PubChem Compound
23724530
PubChem Substance
99443243
ChemSpider
21468899
BindingDB
50343413
ChEBI
79699
ChEMBL
CHEMBL1201182
Therapeutic Targets Database
DAP001222
PharmGKB
PA164746890
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Temsirolimus
ATC Codes
L01XE09 — Temsirolimus
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (402 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentCancer, Advanced1
0RecruitingPreventionTumors, Solid1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentCancer, Advanced3
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1Active Not RecruitingTreatmentCancer, Breast / Colon Neoplasms / Lung Cancers / Malignant Neoplasm of Colon / Melanoma / Neoplasms, Breast / Renal Cancers1
1Active Not RecruitingTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1Active Not RecruitingTreatmentCentral Nervous System / Recurrent Lymphoma / Refractory Lymphomas / Tumors, Solid1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdult Solid Neoplasm / Lung Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Uterine Corpus Sarcoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IV Renal Cell Cancer / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentBrain and Central Nervous System Tumors / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast / Endometrial Cancers / Lung Cancers / Malignant Lymphomas / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancers1
1CompletedTreatmentCancers / Renal Cell Adenocarcinoma1
1CompletedTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma1
1CompletedTreatmentColorectal Adenocarcinoma / Colorectal Cancers1
1CompletedTreatmentEndometrial Papillary Serous Carcinoma / Recurrent Endometrial Carcinoma / Recurrent Renal Cell Cancer / Stage III Endometrial Carcinoma / Stage III Renal Cell Cancer / Stage IV Endometrial Carcinoma / Stage IV Renal Cell Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Hereditary Paraganglioma / Male Breast Cancer / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Pheochromocytoma / Pancreatic Polypeptide Tumor / Paraganglion neoplasm malignant / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Endometrial Carcinoma / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Neuroendocrine Carcinoma of the Skin / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pheochromocytoma / Recurrent Prostate Cancer / Recurrent Renal Cell Cancer / Recurrent Small Cell Lung Cancer / Recurrent Uterine Sarcoma / Regional Gastrointestinal Carcinoid Tumor / Regional Pheochromocytoma / Stage III Cervical Cancer / Stage III Endometrial Carcinoma / Stage III Neuroendocrine Carcinoma of the Skin / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage III Prostate Cancer / Stage III Renal Cell Cancer / Stage III Uterine Sarcoma / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Endometrial Carcinoma / Stage IV Neuroendocrine Carcinoma of the Skin / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Prostate Cancer / Stage IV Renal Cell Cancer / Stage IV Uterine Sarcoma / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentGenital Neoplasms, Female1
1CompletedTreatmentHepatic Complications / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentHepatocellular,Carcinoma1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentMalignant Carcinoma / Neoplasms1
1CompletedTreatmentMelanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentOvarian Sarcoma / Ovarian Stromal Cancer / Recurrent Endometrial Carcinoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Stage III Endometrial Carcinoma / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage IV Endometrial Carcinoma / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentPediatric Solid Tumors1
1CompletedTreatmentRecurrent Adult Hodgkin's Lymphoma1
1CompletedTreatmentRecurrent Melanoma / Recurrent Renal Cell Cancer / Stage IV Melanoma / Stage IV Renal Cell Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRefractory Follicular Lymphoma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRenal Cancers1
1CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentResistant Solid Malignancies2
1CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific2
1RecruitingTreatmentAdvanced Cancers2
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentPatients With Advanced or Metastatic Solid Tumors1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
1TerminatedTreatmentAdenocarcinoma of the Pancreas1
1TerminatedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1TerminatedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentAdvanced/Recurrent Breast Cancer / Cancer, Ovarian / Endometrial Cancers1
1WithdrawnBasic ScienceNeoplasms, Brain1
1WithdrawnTreatmentGliomas / Neoplasms, Brain Stem / Pinealoma1
1WithdrawnTreatmentLiver Cancer1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Oligodendroglioma / Recurrent Adult Brain Neoplasm1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2Active Not RecruitingTreatmentCognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Therapy-Related Toxicity / Tiredness / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2CompletedTreatmentAdenocarcinomas / Neoplasms1
1, 2CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Pilocytic Astrocytoma / Adult Pineal Gland Astrocytoma / Adult Subependymal Giant Cell Astrocytoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL)1
1, 2CompletedTreatmentInoperable HCC1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentRefractory Mantle Cell Lymphoma1
1, 2CompletedTreatmentSarcomas1
1, 2Not Yet RecruitingTreatmentGlioblastoma, Adult1
1, 2RecruitingTreatmentCancer, Advanced / Carcinoma, Colorectal / Endometrial / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Renal Cell Adenocarcinoma / Uterine1
1, 2TerminatedTreatmentAdvanced Cancers1
1, 2TerminatedTreatmentAndrogen-insensitive Prostate Cancer / Castrate-resistant Prostate Cancer (CRPC) / Hormone-Refractory Prostate Cancer / Metastatic Disease / Prostate Cancer / Prostatic Neoplasms1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2WithdrawnTreatmentHepatocellular,Carcinoma1
1, 2WithdrawnTreatmentMantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentAdvanced Rare Tumours1
2Active Not RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Brain Tumor, Recurrent / Glioblastomas / Mixed Gliomas1
2Active Not RecruitingTreatmentChildhood Alveolar Soft-part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Gliosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Neurofibrosarcoma / Childhood Synovial Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma1
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2Active Not RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Positive / Male Breast Carcinoma / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentHER2-mutant Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2Active Not RecruitingTreatmentRecurrent Endometrial Carcinoma1
2Active Not RecruitingTreatmentRenal Cancers1
2Active Not RecruitingTreatmentThyroid Cancers1
2CompletedNot AvailableEndometrioid Carcinoma / MTor Protein1
2CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Endometrial Serous Adenocarcinoma / Localized Non-Resectable Adult Liver Carcinoma / Lung Carcinoid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Pancreatic Gastrinoma / Malignant Pancreatic Glucagonoma / Malignant Pancreatic Insulinoma / Malignant Pancreatic Somatostatinoma / Metastatic Digestive System Neuroendocrine Tumor G1 / Ovarian Carcinosarcoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Pancreatic Alpha Cell Adenoma / Pancreatic Beta Cell Adenoma / Pancreatic Delta Cell Adenoma / Pancreatic G-Cell Adenoma / Pancreatic Polypeptide Tumor / Recurrent Adult Liver Carcinoma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer / Uterine Carcinosarcoma1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Neoplasms, Malignant / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Cell Carcinoma / Endometrial Clear Cell Carcinoma / Endometrial Papillary Serous Carcinoma / Recurrent Endometrial Carcinoma / Stage IIIA Endometrial Carcinoma / Stage IIIB Endometrial Carcinoma / Stage IIIC Endometrial Carcinoma / Stage IVA Endometrial Carcinoma / Stage IVB Endometrial Carcinoma1
2CompletedTreatmentEndometrial Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC1 Uterine Corpus Cancer / Stage IIIC2 Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer1
2CompletedTreatmentFallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentGastrointestinal Stromal Tumors / Recurrent Adult Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentGenital Diseases, Female / Neoplasms, Endometrial / Neoplasms, Ovarian / Ovarian Diseases1
2CompletedTreatmentGlioblastoma Multiforme1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2CompletedTreatmentLeukemias1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Gastrointestinal Carcinoid Tumor / Pulmonary Carcinoid Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma1
2CompletedTreatmentMetastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Osteosarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNon-clear Cell Renal Cell Cancer1
2CompletedTreatmentOvarian Clear Cell Cystadenocarcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2CompletedTreatmentRecurrent Mantle Cell Lymphoma2
2CompletedTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentRelapsed Bladder Cancer1
2CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2Not Yet RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Myeloblastic Leukemia1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentChronic Limb Ischemia1
2SuspendedTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentLiver Cancer1
2TerminatedTreatmentMucosal Melanoma / Recurrent Melanoma / Stage IV Melanoma1
2TerminatedTreatmentMyelodysplastic Syndrome1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Refractory Chronic Lymphocytic Leukemia1
2TerminatedTreatmentRecurrent Uterine Sarcoma / Uterine Carcinosarcoma1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentSquamous Cell Carcinoma (SCC)1
2Unknown StatusTreatmentLymphoma, Hodgkins1
2Unknown StatusTreatmentRecurrent or Refractory Primary CNS Lymphoma1
2Unknown StatusTreatmentRenal Cell Adenocarcinoma1
2Unknown StatusTreatmentUnresectable or Metastatic Hepatocellular Carcinoma1
2WithdrawnTreatmentMelanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
2WithdrawnTreatmentNeoplasms, Hepatic1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentNeoplasms, Kidney / Renal Cell Adenocarcinoma1
3CompletedTreatmentRenal Cell Adenocarcinoma2
3RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3SuspendedTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
4Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
4WithdrawnNot AvailableRenal Cell Adenocarcinoma1
Not AvailableActive Not RecruitingNot AvailableRenal Cell Adenocarcinoma2
Not AvailableCompletedNot AvailableSquamous Cell Carcinoma (SCC)1
Not AvailableCompletedPreventionProstatic Neoplasms1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Metastatic Cancers1
Not AvailableCompletedTreatmentRenal Cell Adenocarcinoma1
Not AvailableCompletedTreatmentTumors, Solid1
Not AvailableRecruitingNot AvailableCarcinoma, Renal Cell, Advanced / Gastrointestinal Stroma Tumors / Lymphoma, Mantle-Cell1
Not AvailableWithdrawnTreatmentHead and Neck Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous25 mg
Injection, solution, concentrateIntravenous30 mg
Kit
LiquidIntravenous25 mg
Prices
Unit descriptionCostUnit
Torisel 25 mg kit1467.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2429020No2009-05-262021-11-13Canada
CA2187024No2004-08-102015-04-14Canada
US8791097Yes2012-11-102032-11-10Us
US8455539Yes2004-01-252024-01-25Us
US5362718Yes1999-08-152019-08-15Us
US8722700Yes2004-01-252024-01-25Us
US8026276Yes2006-07-202026-07-20Us
USRE44768Yes1999-08-152019-08-15Us
US8299116Yes2004-01-252024-01-25Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00235 mg/mLALOGPS
logP4.39ALOGPS
logP7.13ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area241.96 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity277.07 m3·mol-1ChemAxon
Polarizability112.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8908
Blood Brain Barrier-0.9494
Caco-2 permeable-0.664
P-glycoprotein substrateSubstrate0.8122
P-glycoprotein inhibitor IInhibitor0.8098
P-glycoprotein inhibitor IIInhibitor0.7467
Renal organic cation transporterNon-inhibitor0.7636
CYP450 2C9 substrateNon-substrate0.8699
CYP450 2D6 substrateNon-substrate0.8845
CYP450 3A4 substrateSubstrate0.7533
CYP450 1A2 substrateNon-inhibitor0.9126
CYP450 2C9 inhibitorNon-inhibitor0.8957
CYP450 2D6 inhibitorNon-inhibitor0.942
CYP450 2C19 inhibitorNon-inhibitor0.9155
CYP450 3A4 inhibitorNon-inhibitor0.9558
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9398
Ames testNon AMES toxic0.6087
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9522
Rat acute toxicity2.8760 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9703
hERG inhibition (predictor II)Non-inhibitor0.7479
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolide lactams
Sub Class
Not Available
Direct Parent
Macrolide lactams
Alternative Parents
Alpha amino acid esters / Macrolides and analogues / Beta hydroxy acids and derivatives / Piperidines / Oxanes / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Secondary alcohols / Carboxylic acid esters / Cyclic ketones
show 11 more
Substituents
Macrolide lactam / Alpha-amino acid ester / Macrolide / Alpha-amino acid or derivatives / Beta-hydroxy acid / Dicarboxylic acid or derivatives / Hydroxy acid / Oxane / Piperidine / Tertiary carboxylic acid amide
show 25 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
lactam, macrolide (CHEBI:79699)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tfiiic-class transcription factor binding
Specific Function
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly...
Gene Name
MTOR
Uniprot ID
P42345
Uniprot Name
Serine/threonine-protein kinase mTOR
Molecular Weight
288889.05 Da
References
  1. Patard JJ, Pouessel D, Bensalah K, Culine S: Targeted therapy in renal cell carcinoma. World J Urol. 2008 Apr;26(2):135-40. doi: 10.1007/s00345-008-0237-4. Epub 2008 Feb 12. [PubMed:18265991]
  2. Radulovic S, Bjelogrlic SK: Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007 Sep;12 Suppl 1:S151-62. [PubMed:17935273]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on March 19, 2008 10:22 / Updated on November 19, 2017 20:33